Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Fichna, Jakub ^a,d   Bawa, Misha ^b   Thakur, Ganesh A ^e   Tichkule, Ritesh ^e   Makriyannis, Alexandros ^e   McCafferty, Donna Marie ^b   Sharkey, Keith A ^a,b,c   Storr, Martin ^a,f  

^a University of Calgary and Alberta Health Services   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e NORTHEASTERN UNIVERSITY   (United States)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AM 841; CANNABINOID RECEPTOR AGONIST; CB 13; DEXTRAN SULFATE; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; 7'-ISOTHIOCYANATO-11-HYDROXY-1',1'-DIMETHYLHEPTYLHEXAHYDROCANNABINOL; CANNABINOID; CANNABINOID RECEPTOR; DRONABINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL VIABILITY; COLITIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; MALE; MOLECULAR DYNAMICS; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; SPLEEN CELL; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MACROPHAGE;

MUS;

ANIMALS; CANNABINOIDS; DRONABINOL; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; MALE; MICE; PHAGOCYTOSIS; RECEPTORS, CANNABINOID;

EID: 84907546585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109115     Document Type: Article

References (48)

1. Ordas I, Eckmann L, Talamini M., Baumgart DC, Sandborn WJ (2012) Ulcerative colitis. Lancet 380: 1606-1619.
2. Cheifetz AS (2013) Management of active Crohn disease. JAMA 309: 2150-2158.
3. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417-429.
4. Strobach RS, Ross AH, Markin R.S., Zetterman RK, Linder J (1990) Neural patterns in inflammatory bowel disease: an immunohistochemical survey. Mod Pathol 3: 488-493.
5. Mawe GM, Strong DS, Sharkey KA (2009) Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil 21: 481-491.
6. Izzo AA, Sharkey KA (2010) Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38.
7. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327: 535-550.
8. Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547: 267-274.
9. Kaminski NE, Abood ME, Kessler F.K., Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42: 736-742.
10. Bouaboula M, Rinaldi M, Carayon P., Carillon C, Delpech B, et al. (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173-180.
11. Kulkarni-Narla A, Brown DR (2000) Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302: 73-80.
12. Coutts AA, Irving AJ, Mackie K, Pertwee R.G., navi-Goffer S (2002) Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422.
13. Galiegue S, Mary S, Marchand J., Dussossoy D, Carriere D, et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
14. Duncan M, Mouihate A, Mackie K., Keenan CM, Buckley NE, et al. (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastro-intest Liver Physiol 295: G78-G87.
15. Massa F, Marsicano G, Hermann H., Cannich A, Monory K, et al. (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
16. Kimball ES, Schneider CR, Wallace N.H., Hornby PJ (2006) Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291: G364-G371.
17. Storr MA, Keenan CM, Emmerdinger D, Zhang H., Yuce B, et al. (2008) Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 86: 925-936.
18. Wright K, Rooney N, Feeney M., Tate J, Robertson D, et al. (2005) Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453.
19. Storr MA, Keenan CM, Zhang H, Patel K.D., Makriyannis A., et al. (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 15: 1678-1685.
20. Ihenetu K, Molleman A, Parsons M.E., Whelan CJ (2003) Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458: 207-215.
21. Izzo AA, Fezza F, Capasso R., Bisogno T, Pinto L, et al. (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134: 563-570.
22. Mathison R, Ho W, Pittman Q.J., Davison JS, Sharkey KA (2004) Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142: 1247-1254.
23. Picone RP, Khanolkar AD, Xu W, Ayotte L.A., Thakur GA, et al. (2005) (-)-79-Isothiocyanato-11-hydroxy-19, 19-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 68: 1623-1635.
24. Dziadulewicz EK, Bevan SJ, Brain C.T., Coote PR, Culshaw AJ, et al. (2007) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bio-available human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50: 3851-3856.
25. Fichna J, Dicay M, Lewellyn K., Janecka A, Zjawiony JK, et al. (2012) Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 18: 1137-1145.
26. Khan AI, Heit B, Andonegui G., Colarusso P, Kubes P (2005) Lipopolysaccha-ride: a p38 MAPK-dependent disrupter of neutrophil chemotaxis. Microcirculation 12: 421-432.
27. Carballo E, Pitterle DM, Stumpo D.J., Sperling RT, Blackshear PJ (1999) Phagocytic and macropinocytic activity in MARCKS-deficient macrophages and fibroblasts. Am J Physiol 277: C163-C173.
28. Bussolaro D, Filipak NF, Gargioni R, Fernandes L.C., Randi MA, et al. (2008) The immune response of peritoneal macrophages due to exposure to inorganic lead in the house mouse Mus musculus. Toxicol In Vitro 22: 254-260.
29. Szymanski DW, Papanastasiou M, Melchior K., Zvonok N, Mercier RW, et al. (2011) Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. J Proteome Res 10: 4789-4798.
30. Pei Y, Mercier RW, Anday J.K., Thakur GA, Zvonok AM, et al. (2008) Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol 15: 1207-1219.
31. Di Marzo V, De Petrocellis L., Fezza F., Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377-391.
32. Cluny NL, Keenan CM, Duncan M, Fox A., Lutz B, et al. (2010) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. J Pharmacol Exp Ther 334: 973-980.
33. McHugh D, Tanner C, Mechoulam R., Pertwee RG, Ross RA (2008) Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocanna-binoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 73: 441-450.
34. Nilsson O, Fowler CJ, Jacobsson SO (2006) The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. Eur J Pharmacol 547: 165-173.
35. Kurihara R, Tohyama Y, Matsusaka S., Naruse H, Kinoshita E, et al. (2006) Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J Biol Chem 281: 12908-12918.
36. Nathan C (2006) Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6: 173-182.
37. Schwarz H, Blanco FJ, Lotz M (1994) Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55: 107-115.
38. Luo YD, Patel MK, Wiederhold M.D., Ou DW (1992) Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins. Int J Immunopharmacol 14: 49-56.
39. Schatz AR, Lee M, Condie R.B., Pulaski JT, Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142: 278-287.
40. Klein TW, Kawakami Y, Newton C., Friedman H (1991) Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 32: 465-477.
41. Arata S, Klein TW, Newton C, Friedman H (1991) Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sci 49: 473-479.
42. Dignass AU, Baumgart DC, Sturm A (2004) Review article: the aetiopathogen-esis of inflammatory bowel disease-immunology and repair mechanisms. Aliment Pharmacol Ther 20 Suppl 4: 9-17.
43. Carlisle SJ, Marciano-Cabral F, Staab A., Ludwick C, Cabral GA (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2: 69-82.
44. Mann PE, Cohen AB, Finley T.N., Ladman AJ (1971) Alveolar macrophages. Structural and functional differences between nonsmokers and smokers of marijuana and tobacco. Lab Invest 25: 111-120.
45. Lopez-Cepero M, Friedman M, Klein T., Friedman H (1986) Tetrahydrocan-nabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 39: 679-686.
46. McCoy KL, Gainey D, Cabral GA (1995) delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 273: 1216-1223.
47. Cabral GA, Mishkin EM (1989) Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. J Toxicol Environ Health 26: 175-182.
48. Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA (1993) delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15: 371-382.